GWM
HEPA

Geneos Wealth Management’s Hepion Pharmaceuticals HEPA Stock Holding History

Geneos Wealth Management’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5
Closed -$2K – 2264
2022
Q2 		$2K Hold
5
– – ﹤0.01% 2390
2022
Q1 		$6K Hold
5
– – ﹤0.01% 2273
2021
Q4 		$5K Hold
5
– – ﹤0.01% 2400
2021
Q3 		$7K Hold
5
– – ﹤0.01% 2347
2021
Q2 		$9K Hold
5
– – ﹤0.01% 2227
2021
Q1 		$8K Buy
+5
New +$11K ﹤0.01% 2473

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Geneos Wealth Management's HEPA Position: Q3 2022 in Review

Geneos Wealth Management sold out of Hepion Pharmaceuticals (HEPA) in Q3 2022, closing a stake of 5 shares — an estimated $2K sold.

Geneos Wealth Management first reported a position in HEPA in Q1 2021 and held it in 6 quarters. The position peaked at $9K in Q2 2021. 25 funds tracked by Wall St. Rank hold HEPA as of Q3 2022.

  • Geneos Wealth Management reported no remaining Hepion Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Geneos Wealth Management sold 5 Hepion Pharmaceuticals shares in Q3 2022, an estimated $2K.
  • Geneos Wealth Management first reported a position in Hepion Pharmaceuticals in Q1 2021 and held it in 6 quarters.
  • Geneos Wealth Management's Hepion Pharmaceuticals position peaked at $9K in Q2 2021.
  • 25 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q3 2022.

Based on Geneos Wealth Management's 13F filing for Q3 2022, filed 14 Nov 2022.